ArticleBMC complementary medicine and therapies2026
Quercetin parallels ascorbic acid in neuroprotection against manganese-induced toxicity in Drosophila melanogaster.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quercetin (QCT) is a dietary flavonoid with reported antioxidant and neuroprotective properties, but direct comparisons with established antioxidants, such as ascorbic acid (AA), under chemically induced neurotoxic stress are limited. We compared Quercetin and AA in adult D. melanogaster using a manganese (Mn)-sensitized model to capture Parkinson-like motor and biochemical vulnerability. Treatment groups comprised: Control; Mn (15 mM); AA (10 mM); Quercetin 0.5 mM/3.0 mM; AA + Mn; Quercetin 0.5 mM/3.0 mM + Mn. Each vial represented an independent biological replicate (mixed sex); biochemical and genomic assays were performed using n = 4 vials/group. Outcomes included survival, locomotor performance (RING), redox endpoints (GSH/GSSG, H₂O₂, MDA, SOD, CAT), neuromodulators (AChE, dopamine), DNA fragmentation index (DFI), and advanced glycation end-products (AGEs). Omnibus tests (ANOVA or Kruskal-Wallis) were followed by Tukey HSD or Dunn-style pairwise comparisons; two pre-specified pooled contrasts were tested with Welch comparisons and effect sizes reported (mean differences, 95% CI, Cohen’s d); pooled p-values were adjusted (Holm, BH). Quercetin and AA produced comparable protective effects, as both preserved climbing behaviour and partially restored the redox balance versus Mn. One Tukey-adjusted pairwise result reached significance (Control vs. quercetin low + Mn for DFI, p_adj = 0.049). A pooled contrast showed reduced H₂O₂ for Quercetin (Q_all vs. AA_all: mean diff = 0.498 µmol·g⁻¹, 95% CI 0.153–0.844; Welch t(13.27) = 3.11, p = 0.0082; d ≈ 1.38), but this and other pooled signals did not survive conservative family-wise correction across all pooled tests. In conclusion, although they are overall comparable, our data suggest that quercetin may have a superior, specific effect on reducing H₂O₂ and protecting DNA integrity (DFI). These endpoints are now prioritized for confirmatory studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.